Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company UroGen Pharma Ltd.
DescriptionSustained release formulation of a high dose Mitomycin C
Molecular Target
Mechanism of Action 
Therapeutic Modality 
Latest Stage of DevelopmentPhase II
Standard IndicationBladder cancer
Indication DetailsTreat low grade non-muscle invasive bladder cancer (NMIBC)
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today